Myositis-specific autoantibodies: overview and recent developments

Myositis-specific autoantibodies (MSAs) are found in almost half the patients with an idiopathic inflammatory myopathy (IIM). Several clinical and epidemiological studies have suggested that MSAs are associated with specific clinical characteristics. Some of these associations are well-defined and are of clinical significance (eg, anti-Jo-1 and the anti-synthetase syndrome), others are less well established and can cause unnecessary anxiety for both patients and physicians (eg, anti-SRP and cardiac involvement). In this review, an overview is given of the various MSAs, their biochemical background, their clinical usefulness, and the promises they hold for a better understanding of IIM.

[1]  Koen Vos,et al.  How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. , 2002, Arthritis and rheumatism.

[2]  B. V. van Engelen,et al.  Anti-Jo-1 positive inclusion body myositis with a marked and sustained clinical improvement after oral prednisone , 2001, Journal of neurology, neurosurgery, and psychiatry.

[3]  E. Girbal-Neuhauser,et al.  The Major Synovial Targets of the Rheumatoid Arthritis-Specific Antifilaggrin Autoantibodies Are Deiminated Forms of the α- and β-Chains of Fibrin1 , 2001, The Journal of Immunology.

[4]  Amy E. Cox,et al.  The DNA mismatch repair enzyme PMS1 is a myositis-specific autoantigen. , 2001, Arthritis and rheumatism.

[5]  D. Isenberg,et al.  Autoantibody profiles in the sera of European patients with myositis , 2001, Annals of the rheumatic diseases.

[6]  F. Breedveld,et al.  Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis. , 2001, Arthritis and rheumatism.

[7]  T. Mimori,et al.  Myositis and interstitial lung disease associated with autoantibody to a transfer RNA-related protein Wa. , 2000, The Journal of rheumatology.

[8]  Van Venrooij Wj,et al.  Autoantibody testing in the evaluation of idiopathic inflammatory myopathies: myositis-specific autoantibodies: are they ready to leave the bench for the bedside? , 2000 .

[9]  T. Kveder,et al.  Immunoserological aspects of idiopathic inflammatory muscle disease. , 2000, Wiener klinische Wochenschrift.

[10]  M. V. van Leeuwen,et al.  The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. , 2000, Arthritis and rheumatism.

[11]  E. Gromnica-ihle,et al.  Clinical and Serological Aspects of Patients with Anti-Jo-1 Antibodies – an Evolving Spectrum of Disease Manifestations , 2000, Clinical Rheumatology.

[12]  R. Wada,et al.  Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[13]  P. Roepstorff,et al.  Heterogeneous nuclear ribonucleoproteins C1/C2 identified as autoantigens by biochemical and mass spectrometric methods , 2000, Arthritis research.

[14]  R. Rodenburg,et al.  Cell death: a trigger of autoimmunity? , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.

[15]  B. V. van Engelen,et al.  Myositis during long-term interferon-α treatment , 2000, Neurology.

[16]  M. Mamula,et al.  Molecular mimicry and the role of B lymphocytes in the processing of autoantigens , 2000, Cellular and Molecular Life Sciences CMLS.

[17]  E. Girbal-Neuhauser,et al.  In the rheumatoid pannus, anti‐filaggrin autoantibodies are produced by local plasma cells and constitute a higher proportion of IgG than in synovial fluid and serum , 2000, Clinical and experimental immunology.

[18]  P. Anderson,et al.  Death, autoantigen modifications, and tolerance , 2000, Arthritis research.

[19]  B. V. van Engelen,et al.  Autoantibody testing in the evaluation of idiopathic inflammatory myopathies: myositis-specific autoantibodies: are they ready to leave the bench for the bedside? , 2000, Journal of clinical neuromuscular disease.

[20]  J. Hazes,et al.  The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. , 2000, Arthritis and rheumatism.

[21]  B. V. van Engelen,et al.  Myositis during long-term interferon-alpha treatment. , 2000, Neurology.

[22]  J. Jacobs,et al.  The prognostic value of the antiperinuclear factor, anti-citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis. , 1999, Clinical and experimental rheumatology.

[23]  M. Mathews,et al.  Inosine and N1-methylinosine within a synthetic oligomer mimicking the anticodon loop of human tRNA(Ala) are major epitopes for anti-PL-12 myositis autoantibodies. , 1999, RNA.

[24]  T. Mimori,et al.  Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. , 1999, Journal of immunology.

[25]  D. Reinberg,et al.  The Dermatomyositis-Specific Autoantigen Mi2 Is a Component of a Complex Containing Histone Deacetylase and Nucleosome Remodeling Activities , 1998, Cell.

[26]  MD G. J. D. Hengstman,et al.  Presence of the anti–Jo‐1 autoantibody excludes inclusion body myositis , 1998, Annals of neurology.

[27]  B. V. van Engelen,et al.  Frequent occurrence of anti-tRNA(His) autoantibodies that recognize a conformational epitope in sera of patients with myositis. , 1998, Arthritis and rheumatism.

[28]  P. Anderson,et al.  Posttranslational protein modifications, apoptosis, and the bypass of tolerance to autoantigens. , 1998, Arthritis and rheumatism.

[29]  F. V. D. van den Hoogen,et al.  Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. , 1998, The Journal of clinical investigation.

[30]  I. Hausmanowa-Petrusewicz,et al.  Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. , 1997, Arthritis and rheumatism.

[31]  R. Barohn,et al.  The therapeutic dilemma of inclusion body myositis , 1997, Neurology.

[32]  T. Mimori.  Structures targeted by the immune system in myositis. , 1996, Current opinion in rheumatology.

[33]  J. Reveille,et al.  Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. , 1996, Arthritis and rheumatism.

[34]  Marinos C. Dalakas.  Immunopathogenesis of inflammatory myopathies , 1995, Annals of neurology.

[35]  I. Targoff,et al.  Immune manifestations of inflammatory muscle disease. , 1994, Rheumatic diseases clinics of North America.

[36]  I. Targoff,et al.  Myositis-associated antigens. Aminoacyl-tRNA synthetases Jo-1, PL-7, PL-12, EJ, and OJ , 1994 .

[37]  F. Miller.  Myositis-Specific Autoantibodies: Touchstones for Understanding the Inflammatory Myopathies , 1993 .

[38]  M. Joffe,et al.  Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. , 1993, The American journal of medicine.

[39]  Charles Pj,et al.  The Consensus Workshops for the Detection of Autoantibodies to Intracellular Antigens in Rheumatic Diseases: 1989-1992. , 1992 .

[40]  T. Mimori,et al.  Autoantibodies to small nuclear and cytoplasmic ribonucleoproteins in Japanese patients with inflammatory muscle disease. , 1992, Arthritis and rheumatism.

[41]  W. V. van Venrooij,et al.  The Consensus Workshops for the Detection of Autoantibodies to Intracellular Antigens in Rheumatic Diseases: 1989-1992. , 1992, Clinical and experimental rheumatology.

[42]  M. Dalakas.  Polymyositis, dermatomyositis and inclusion-body myositis. , 1991, The New England journal of medicine.

[43]  M. Dalakas,et al.  A New Approach to the Classification of Idiopathic Inflammatory Myopathy: Myositis‐Specific Autoantibodies Define Useful Homogeneous Patient Groups , 1991, Medicine.

[44]  T. Mimori,et al.  A novel autoantibody reactive with a 48 kDa tRNA associated protein in patients with scleroderma. , 1991, The Journal of rheumatology.

[45]  I. Targoff,et al.  Antibody to signal recognition particle in polymyositis. , 1990, Arthritis and rheumatism.

[46]  I. Targoff.  Autoantibodies to aminoacyl-transfer RNA synthetases for isoleucine and glycine. Two additional synthetases are antigenic in myositis. , 1990, Journal of immunology.

[47]  F. Arnett,et al.  Anti-KJ: a new antibody associated with the syndrome of polymyositis and interstitial lung disease. , 1989, The Journal of clinical investigation.

[48]  T. Mimori,et al.  Characterization of human autoantibodies that selectively precipitate the 7SL RNA component of the signal recognition particle. , 1987, Journal of immunology.

[49]  G. Blobel,et al.  Human autoantibodies reactive with the signal-recognition particle. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[50]  M. Mathews,et al.  Autoantibodies against alanyl-tRNA synthetase and tRNAAla coexist and are associated with myositis , 1986, The Journal of experimental medicine.

[51]  I. Targoff,et al.  The association between Mi-2 antibodies and dermatomyositis. , 1985, Arthritis and rheumatism.

[52]  F. Arnett,et al.  Multiplicity of antibodies in myositis sera. , 1984, Arthritis and rheumatism.

[53]  M. Mathews,et al.  Anti-threonyl-tRNA synthetase, a second myositis-related autoantibody , 1984, The Journal of experimental medicine.

[54]  M. Mathews,et al.  Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity , 1983, Nature.

[55]  M. Reichlin,et al.  Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system. , 1980, Arthritis and rheumatism.